{"title":"Prognostic Value of Serum β2-Microglobulin in Predicting Survival of Patients with Diffuse Large B-Cell Lymphoma.","authors":"Jun W Zhong, Xiang Weng, Li Chen","doi":"10.7754/Clin.Lab.2024.240907","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study investigated the predictive value of β2-microglobulin (β2-MG) on the prognosis of diffuse large B-cell lymphoma (DLBCL) patients.</p><p><strong>Methods: </strong>Patients with DLBCL diagnosed by pathologic biopsy were collected from January 2021 through December 2022, and a total of 98 patients were finally included. The 98 patients were grouped according to their prognosis, i.e., into the survival group (n = 69) and death group (n = 29). The critical value of β2-MG for survival in DLBCL patients was obtained by ROC curve. Kaplan Meier curve was plotted to analyze the relationship between β2-MG and the overall survival of DLBCL patients, and a one-way test was performed to examine the clinical data of the patients. Independent predictors affecting the prognosis of DLBCL patients were screened using unifactorial and multifactorial Cox regression analysis. R 4.2.1 software was used to refit the constructed column-line graph prediction model and internal validation.</p><p><strong>Results: </strong>The critical value of β2-MG for survival in DLBCL patients was 3.285 µg/L, obtained by ROC curve. All patients were categorized into the following two groups: β2-MG ≤ 3.285 group (n = 75) and β2-MG > 3.285 group (n = 23). During the follow-up period, 9 endpoint events occurred in the β2-MG ≤ 3.285 group and 20 endpoint events occurred in the β2-MG > 3.285 group. The β2-MG ≤ 3.285 group had a higher overall survival rate than the β2-MG > 3.285 group. High levels of β2-MG, LDH, and CRP were independent prognostic influences affecting overall survival in DLBCL patients. β2-MG, LDH, and CRP were combined to construct the prognostic prediction model, and there was a better consistency between the predicted probability and the actual results.</p><p><strong>Conclusions: </strong>Poor treatment prognosis of DLBCL patients is closely related to abnormally elevated levels of β2-MG. High levels of β2-MG, LDH, and CRP are independent risk factors for disease progression and prognostic survival in DLBCL patients.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 3","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240907","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: This study investigated the predictive value of β2-microglobulin (β2-MG) on the prognosis of diffuse large B-cell lymphoma (DLBCL) patients.
Methods: Patients with DLBCL diagnosed by pathologic biopsy were collected from January 2021 through December 2022, and a total of 98 patients were finally included. The 98 patients were grouped according to their prognosis, i.e., into the survival group (n = 69) and death group (n = 29). The critical value of β2-MG for survival in DLBCL patients was obtained by ROC curve. Kaplan Meier curve was plotted to analyze the relationship between β2-MG and the overall survival of DLBCL patients, and a one-way test was performed to examine the clinical data of the patients. Independent predictors affecting the prognosis of DLBCL patients were screened using unifactorial and multifactorial Cox regression analysis. R 4.2.1 software was used to refit the constructed column-line graph prediction model and internal validation.
Results: The critical value of β2-MG for survival in DLBCL patients was 3.285 µg/L, obtained by ROC curve. All patients were categorized into the following two groups: β2-MG ≤ 3.285 group (n = 75) and β2-MG > 3.285 group (n = 23). During the follow-up period, 9 endpoint events occurred in the β2-MG ≤ 3.285 group and 20 endpoint events occurred in the β2-MG > 3.285 group. The β2-MG ≤ 3.285 group had a higher overall survival rate than the β2-MG > 3.285 group. High levels of β2-MG, LDH, and CRP were independent prognostic influences affecting overall survival in DLBCL patients. β2-MG, LDH, and CRP were combined to construct the prognostic prediction model, and there was a better consistency between the predicted probability and the actual results.
Conclusions: Poor treatment prognosis of DLBCL patients is closely related to abnormally elevated levels of β2-MG. High levels of β2-MG, LDH, and CRP are independent risk factors for disease progression and prognostic survival in DLBCL patients.
期刊介绍：
Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
